Ken Griffin Replimune Group, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$8.09 - $11.23 $8,090 - $11,230	1,000 Added 10.87%	10,200 $111,000
Q2 2024 Aug 14, 2024	SELL	$5.01 - $9.46 $45,090 - $85,140	-9,000 Reduced 49.45%	9,200 $82,000
Q1 2024 May 15, 2024	BUY	$6.87 - $9.31 $4,122 - $5,586	600 Added 3.41%	18,200 $148,000
Q4 2023 Feb 14, 2024	SELL	$6.75 - $16.18 $585,900 - $1.4 Million	-86,800 Reduced 83.14%	17,600 $148,000
Q3 2023 Nov 14, 2023	BUY	$15.96 - $22.18 $1.46 Million - $2.03 Million	91,600 Added 715.63%	104,400 $1.79 Million
Q2 2023 Aug 14, 2023	BUY	$15.65 - $24.1 $92,335 - $142,190	5,900 Added 85.51%	12,800 $297,000
Q1 2023 May 15, 2023	SELL	$17.48 - $29.09 $1.37 Million - $2.29 Million	-78,600 Reduced 91.93%	6,900 $121,000
Q4 2022 Feb 14, 2023	BUY	$17.09 - $27.91 $5,127 - $8,373	300 Added 0.35%	85,500 $2.33 Million
Q3 2022 Nov 14, 2022	BUY	$15.6 - $21.15 $57,720 - $78,255	3,700 Added 4.54%	85,200 $1.47 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $616M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.